FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 345 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Sex, intimacy and cancer – That Cancer Conversation April 28, 2023 Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for... October 20, 2021 Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast... October 25, 2022 Teclistamab Results in a High Rate of Deep and Durable Response... August 22, 2022 Load more HOT NEWS A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival... Metastasis Likely Caused by Lack of Oxygen in Cancerous Tumors, Study... Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with... French Senate Committee Backs ESMO Call to Revise EU Regulation to...
